ArticleJournal of tissue engineering and regenerative medicine2023
MiR-34a-Functionalized Hydroxyapatite by Lyophilization Promoted Bone Regeneration in Irradiated Bone Defects.
Article in Journal of tissue engineering and regenerative medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rehabilitation of bone defects after radiotherapy requires the development of osteoinductive bone substitutes. MicroRNA could be used as an osteogenic factor to fabricate functional materials for bone regeneration. In this study, we used miR-34a to enhance bone regeneration after irradiation. We lyophilized lipofectamine-agomiR-34a lipoplexes on hydroxyapatite (HA) to develop miR-34a-functionalized hydroxyapatite (HA-agomiR-34a). The morphology was observed by scanning electron microscope and atomic force microscope. Fluorescence microscopy confirmed the retention of agomiR-34a on the surface of HA. HA-agomiR-34a showed high transfection efficiency and good biocompatibility. HA-agomiR-34a enhanced the osteoblastic differentiation of radiation-impaired bone marrow stromal cells (BMSCs). Implantation of HA-agomiR-34a promoted bone regeneration in irradiated bone defects. HA-agomiR-34a may be a novel and safe bone substitute to promote the reconstruction of bone defects after radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.